Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has reported that a thrombin receptor antagonist was shown to be a potent inhibitor of platelet aggregation in a sub-analysis of its Phase II trial for percutaneous coronary intervention.
Subscribe to our email newsletter
The pharmacokinetic and pharmacodynamic analysis, conducted by the University of Tennessee Health Science Center, showed that SCH 530348 (TRA), a potent thrombin receptor antagonist, demonstrated sustained, dose-dependent, specific agonist-induced inhibition of platelet aggregation in blood samples from patients undergoing non-urgent percutaneous coronary intervention (PCI). The results were presented at the American Heart Association Scientific Sessions in Orlando, FL.
Rick Veltri, group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough research institute, said: “Despite recent advances in cardiovascular care, current levels of morbidity and mortality make it clear that an unmet medical need exists for patients with acute coronary syndromes and those at risk of atherothrombosis. We believe these results add to the evidence indicating that TRA may be a promising therapeutic option for patients with unstable angina and non-ST elevation MI undergoing PCI.”